TY - JOUR
T1 - Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents
T2 - The results of the KKESH international collaborative retina study group
AU - Kozak, Igor
AU - Mansour, Ahmad
AU - Diaz, Rocio I.
AU - Calzada, Jorge I.
AU - Pichi, Francesco
AU - Cruz-Villegas, Vanessa
AU - Diaz-Llopis, Manuel
AU - Chhablani, Jay
AU - Martinez-Cartier, Mauricio
AU - Meerhoff, Martin
AU - Mieler, William F.
AU - Arevalo, J. Fernando
AU - Al Kahtani, Eman
AU - Ghazi, Nicola
AU - Nowilaty, Sawsan
AU - Al Rashaed, Saba
AU - Al-Dhibi, Hassan A.
AU - Al-Zahrani, Yahya A.
AU - Gupta, Vishali
AU - Al-Kahtani, Sultan Ahmad
AU - Al-Marzoog, Naif Abdullah
AU - Al-Robaie, Abdullah Saad
AU - Al-Sulaiman, Sulaiman
AU - Al-Abdullah, Abdulelah
AU - Al-Bar, Ahmad
AU - Al-Dhafiri, Yousef
AU - Al-Qahtani, Abdullah
AU - Al-Rubaie, Khalid
AU - Al-Shahrani, Saeed
AU - Al-Shehri, Maha
AU - Younis, Muhammad
AU - Heriot, Wilson
AU - Hall, Anthony
AU - Mackensen, Friederike
AU - Ziemssen, Focke
AU - Mercé, Emilie
AU - Anand, Rajiv
AU - Ahmadieh, Hamid
AU - Mataix, Jorge
AU - Nucci, Paolo
AU - Sarraf, David
AU - Giuliari, Gian Paolo
AU - Albini, Thomas A.
N1 - Publisher Copyright:
Copyright © by Ophthalmic Communications Society, Inc.
PY - 2014/10/12
Y1 - 2014/10/12
N2 - PURPOSE:: To evaluate safety and clinical results of intravitreal antiangiogenic agents for choroidal neovascularization in pediatric patients. METHODS:: Retrospective, multicenter, interventional case series. A total of 45 eyes of 39 pediatric patients with choroidal neovascularization of various etiologies were treated with intravitreal injection of antiangiogenic agents (1.25 mg per 0.05 mL of bevacizumab or 0.5 mg per 0.05 mL of ranibizumab). RESULTS:: There were 24 girls and 15 boys with group median age of 13 years (range, 3-17 years). Mean follow-up period was 12.8 months (range, 3-60 months). Median visual acuity in terms of logarithm of the minimum angle of resolution at presentation and last follow-up was 0.87 and 0.7, respectively (P = 0.0003). Mean and median number of injections received over the follow-up period was 2.2 and 1, respectively. At the last follow-up, 22 eyes (48%) gained more than 3 lines of vision and 27 eyes (60%) had final visual acuity 20/50 or better. Nine eyes (20%) did not improve and had severe vision loss (20/200 or worse). CONCLUSION:: Intravitreal antiangiogenic therapy for choroidal neovascularization in pediatric patients seems temporarily safe and effective in majority of affected eyes. Because of the rarity and character of this condition, it is unlikely that any clinical trials will soon take place to study this or other treatment option.
AB - PURPOSE:: To evaluate safety and clinical results of intravitreal antiangiogenic agents for choroidal neovascularization in pediatric patients. METHODS:: Retrospective, multicenter, interventional case series. A total of 45 eyes of 39 pediatric patients with choroidal neovascularization of various etiologies were treated with intravitreal injection of antiangiogenic agents (1.25 mg per 0.05 mL of bevacizumab or 0.5 mg per 0.05 mL of ranibizumab). RESULTS:: There were 24 girls and 15 boys with group median age of 13 years (range, 3-17 years). Mean follow-up period was 12.8 months (range, 3-60 months). Median visual acuity in terms of logarithm of the minimum angle of resolution at presentation and last follow-up was 0.87 and 0.7, respectively (P = 0.0003). Mean and median number of injections received over the follow-up period was 2.2 and 1, respectively. At the last follow-up, 22 eyes (48%) gained more than 3 lines of vision and 27 eyes (60%) had final visual acuity 20/50 or better. Nine eyes (20%) did not improve and had severe vision loss (20/200 or worse). CONCLUSION:: Intravitreal antiangiogenic therapy for choroidal neovascularization in pediatric patients seems temporarily safe and effective in majority of affected eyes. Because of the rarity and character of this condition, it is unlikely that any clinical trials will soon take place to study this or other treatment option.
KW - antiangiogenic therapy
KW - children
KW - choroidal neovascularization
UR - http://www.scopus.com/inward/record.url?scp=84925286376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925286376&partnerID=8YFLogxK
U2 - 10.1097/IAE.0000000000000200
DO - 10.1097/IAE.0000000000000200
M3 - Article
C2 - 24978669
AN - SCOPUS:84925286376
SN - 0275-004X
VL - 34
SP - 2044
EP - 2052
JO - Retina
JF - Retina
IS - 10
ER -